Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for
tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from
dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more tumor
cells.
PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in
treating patients who have stage IV or recurrent breast cancer.